Sign In
Buy ARGX
$844.50
+13.71 (+1.65%)
At Close: Aug 04, 2026
argenx to Present at Upcoming Investor Conferences
01:00am, Monday, 27'th Feb 2023
February 2 7 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
06:00am, Thursday, 23'rd Feb 2023 GlobeNewswire Inc.
February 23, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
01:00am, Thursday, 23'rd Feb 2023
February 23 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,
Geron (GERN) to Report Q4 Earnings: What's in the Cards?
03:40pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
Devoid of marketed drugs, investors will focus on updates on Geron's (GERN) lead pipeline candidate when it reports its fourth-quarter earnings.
Perrigo (PRGO) to Report Q4 Earnings: What's in the Cards?
04:54pm, Monday, 20'th Feb 2023 Zacks Investment Research
Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.
Immunovant Could Potentially Be An M&A Target, Writes Analyst
06:14pm, Wednesday, 15'th Feb 2023 Benzinga
Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ: IMVT) with an Overweight rating and a price target of $30.
The company's pipeline includes batoclimab (IMVT-1401) and IMVT-1402, f
argenx: Priority Review Voucher Goes To Waste And Why SC Efgartigimod Is Important
01:10pm, Monday, 06'th Feb 2023
argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
06:00am, Friday, 27'th Jan 2023 GlobeNewswire Inc.
January 27, 2023
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
06:30pm, Monday, 16'th Jan 2023 GlobeNewswire Inc.
January 16, 2023
Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?
09:41am, Friday, 13'th Jan 2023 Zacks Investment Research
Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest
Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance
02:47pm, Thursday, 12'th Jan 2023 Zacks Investment Research
Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the company's guidance fell short of Wall Street expectations.
argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?
05:00pm, Tuesday, 10'th Jan 2023 Zacks Investment Research
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Analyst Ratings for argenx
02:01pm, Tuesday, 10'th Jan 2023 Benzinga
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
3
0
0
0
Last 30D
1
0
0
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
01:48pm, Tuesday, 10'th Jan 2023 Benzinga
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 i
argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?
01:32pm, Tuesday, 10'th Jan 2023
argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
